Desai
Pharmaceuticals
Toxicon
Belgium
Biography
Dr. Desai managed oncology drug research programs at the Dana-Farber Cancer Institute in Boston. It is through his expertise that Toxikon became established in life sciences and has continued to advance innovations in the pharmaceutical, biotechnology, and medical device industries for more than 30 years. Throughout its history, Toxikon has evolved to meet the challenges of life science industries. In 1987, Toxikon acquired the former American Biogenics, Inc., of Woburn, MA. This facility was part of the National Toxicology Program, and Toxikon expanded its toxicology and analytical capabilities from 1987 through 1995.
Research Interest
His research interests reflect in his wide range of publications in various national and international journals.
